Birchview Capital, LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1618205) · Explore on the interactive board
Birchview Capital, LP disclosed 72 US equity positions worth $213.8m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is KLAC at 25.2% of the reported book, followed by BMY, LRCX. The top ten holdings are 59.9% of the book, and the portfolio behaves like about 12 equal-weight positions. Versus the prior filing it opened 14 new positions, added to 13, reduced 18 and exited 15. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Birchview Capital, LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 14 new, 13 added, 18 reduced, 15 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | KLAC KLA CORPORATION | Technology | 25.2% | $53.8m | 178,471 | 798% | added |
| 2 | BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 8.0% | $17.1m | 297,243 | -3% | reduced |
| 3 | LRCX LAM RESEARCH CORPORATION | Technology | 7.1% | $15.2m | 35,000 | -3% | reduced |
| 4 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 3.2% | $6.8m | 385,900 | -13% | reduced |
| 5 | SLDB SOLID BIOSCIENCES INC | Healthcare | 3.1% | $6.7m | 666,196 | 6% | added |
| 6 | BDSX BIODESIX INC | 3.0% | $6.5m | 286,804 | 0% | held | |
| 7 | STOK STOKE THERAPEUTICS INC | Healthcare | 2.7% | $5.8m | 178,110 | -15% | reduced |
| 8 | OVV OVINTIV INC | Energy | 2.6% | $5.7m | 107,500 | 0% | held |
| 9 | NKTR NEKTAR THERAPEUTICS | Healthcare | 2.6% | $5.7m | 81,000 | 161% | added |
| 10 | CORT CORCEPT THERAPEUTICS INC | Healthcare | 2.3% | $5.0m | 57,200 | 21% | added |
| 11 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 2.1% | $4.6m | 27,190 | 0% | held |
| 12 | PRTA PROTHENA CORP PLC | Healthcare | 2.1% | $4.4m | 449,019 | 0% | held |
| 13 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 2.0% | $4.3m | 171,000 | 0% | held |
| 14 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 2.0% | $4.3m | 35,018 | 0% | held |
| 15 | CMPX COMPASS THERAPEUTICS INC | 1.7% | $3.7m | 1,675,000 | 14% | added | |
| 16 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 1.3% | $2.8m | 408,100 | -0% | held |
| 17 | ALKS ALKERMES PLC | Healthcare | 1.2% | $2.6m | 50,000 | 0% | held |
| 18 | HALO HALOZYME THERAPEUTICS INC | Healthcare | 1.2% | $2.6m | 33,251 | 229% | added |
| 19 | CLDX CELLDEX THERAPEUTICS INC | Healthcare | 1.2% | $2.6m | 69,900 | -0% | held |
| 20 | CYTK CYTOKINETICS INC | Healthcare | 1.2% | $2.6m | 30,000 | 0% | held |
| 21 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 1.2% | $2.5m | 199,000 | -9% | reduced |
| 22 | VERA VERA THERAPEUTICS INC | Healthcare | 1.2% | $2.5m | 57,758 | 31% | added |
| 23 | UTHR UNITED THERAPEUTICS CORP | Healthcare | 1.1% | $2.4m | 4,506 | 0% | held |
| 24 | ZBIO ZENAS BIOPHARMA INC | 1.1% | $2.4m | 93,601 | 34% | added | |
| 25 | UNIQURE NV | 1.1% | $2.3m | 50,697 | -50% | reduced | |
| 26 | PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC | Healthcare | 1.1% | $2.3m | 1,350,000 | -10% | reduced |
| 27 | ABVX ABIVAX SA | Healthcare | 1.1% | $2.3m | 17,000 | – | new |
| 28 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 1.0% | $2.2m | 220,000 | – | new |
| 29 | BIIB BIOGEN INC | Healthcare | 0.9% | $1.9m | 9,000 | 80% | added |
| 30 | EQT EQT CORPORATION | Energy | 0.9% | $1.8m | 34,619 | 0% | held |
| 31 | BIOA BIOAGE LABS INC | 0.8% | $1.7m | 69,000 | – | new | |
| 32 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 0.8% | $1.6m | 29,000 | -1% | reduced |
| 33 | QDELUSD QUIDELORTHO CORP | 0.7% | $1.6m | 89,377 | 8% | added | |
| 34 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 0.7% | $1.5m | 6,000 | 0% | held |
| 35 | FHTX FOGHORN THERAPEUTICS INC | Healthcare | 0.6% | $1.4m | 281,937 | 0% | held |
| 36 | BCYC BICYCLE THERAPEUTICS PLC | Healthcare | 0.6% | $1.3m | 313,616 | -32% | reduced |
| 37 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.6% | $1.3m | 24,000 | -76% | reduced |
| 38 | XENE XENON PHARMACEUTICALS INC | Healthcare | 0.6% | $1.3m | 21,032 | 0% | held |
| 39 | NVO NOVO NORDISK A/S | Healthcare | 0.5% | $1.2m | 24,000 | – | new |
| 40 | FCX FREEPORT-MCMORAN CL-B | Basic Materials | 0.5% | $1.1m | 18,035 | -0% | held |
| 41 | IMNM IMMUNOME INC | Healthcare | 0.5% | $1.1m | 50,000 | 0% | held |
| 42 | PHVS PHARVARIS N V | Healthcare | 0.5% | $1.0m | 29,847 | 0% | held |
| 43 | HROW HARROW HEALTH INC | 0.5% | $1.0m | 24,000 | 0% | held | |
| 44 | ADAG ADAGENE INC | 0.5% | $1.0m | 240,000 | – | new | |
| 45 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 0.4% | $940.8k | 20,000 | – | new |
| 46 | SLN SILENCE THERAPEUTICS PLC | 0.4% | $782.0k | 71,218 | – | new | |
| 47 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 0.3% | $651.0k | 8,741 | 1% | added |
| 48 | FDMT 4D MOLECULAR THERAPEUTICS INC | Healthcare | 0.3% | $645.1k | 48,505 | – | new |
| 49 | URGN UROGEN PHARMA LTD | Healthcare | 0.3% | $606.7k | 16,487 | – | new |
| 50 | PHAT PHATHOM PHARMACEUTICALS INC | Healthcare | 0.3% | $596.8k | 55,000 | -72% | reduced |
What did Birchview Capital, LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| NVCR NOVOCURE LTD | 19.1% | $2.2m |
| ENGENE HOLDINGS INC | 14.8% | $1.7m |
| RARE ULTRAGENYX PHARMACEUTICAL INC | 11.3% | $1.3m |
| 4XC1 KALVISTA PHARMACEUTICALS INC | 9.9% | $1.1m |
| VSTM VERASTEM INC | 6.9% | $795.0k |
| APGE APOGEE THERAPEUTICS INC | 6.6% | $757.5k |
| APLSUSD APELLIS PHARMACEUTICALS INC | 4.9% | $563.2k |
| IDYA IDEAYA BIOSCIENCES INC | 4.9% | $561.8k |
| RCUS ARCUS BIOSCIENCES INC | 4.8% | $559.2k |
| RGNX REGENXBIO INC | 4.8% | $555.3k |
| RCKT ROCKET PHARMACEUTICALS INC | 3.9% | $454.8k |
| VRDN VIRIDIAN THERAPEUTICS INC | 3.4% | $393.2k |
| OMGBP OUTSET MEDICAL INC | 3.3% | $379.7k |
| PHR PHREESIA INC | 1.0% | $119.8k |
| ZNTL ZENTALIS PHARMACEUTICALS INC | 0.4% | $41.0k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 52.8% |
| Technology | 32.3% |
| Energy | 3.5% |
| Basic Materials | 0.5% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Birchview Capital, LP's portfolio?
Across every quarter Birchview Capital, LP has filed, its median largest position is 20.9% of the book and its median top-ten weight is 57.3%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 15.0 completed holding spells, the median lasted 1.0 quarters; 72.0 positions are still open and their final length is unknown.